A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo

Less than a third of patients with acute myeloid leukemia (AML) are cured by chemotherapy and/or hematopoietic stem cell transplantation, highlighting the need to develop more efficient drugs. The low efficacy of standard treatments is associated with inadequate depletion of CD34(+) blasts and leuke...

Descripción completa

Detalles Bibliográficos
Autores principales: Arruda, Lucas C. M., Stikvoort, Arwen, Lambert, Melanie, Jin, Liqing, Rivera, Laura Sanchez, Alves, Renato M. P., de Moura, Tales Rocha, Mim, Carsten, Lehmann, Sören, Axelsson-Robertson, Rebecca, Dick, John E., Mattsson, Jonas, Önfelt, Björn, Carlsten, Mattias, Uhlin, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335119/
https://www.ncbi.nlm.nih.gov/pubmed/35142149
http://dx.doi.org/10.3324/haematol.2021.279486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335119/
https://www.ncbi.nlm.nih.gov/pubmed/35142149
http://dx.doi.org/10.3324/haematol.2021.279486

Ejemplares similares